ARTICLE | Clinical News
Seebri Breezhaler glycopyrronium bromide regulatory update
January 26, 2015 8:00 AM UTC
Vectura said Novartis submitted an NDA last quarter to FDA for NVA237 for long-term maintenance of chronic obstructive pulmonary disease (COPD). Vectura is eligible to receive a milestone payment upon...